Hims & Hers Health: Questions Remain About Compounding Viability Post Resolution of Semaglutide Shortage

Published on Feb 21, 2025

The Food and Drug Administration announced on Feb. 21 that the years-long shortage of semaglutide, the active ingredient in Novo Nordisk’s blockbuster weight-loss injections Ozempic and Wegovy, had been resolved.

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2025 The Capitol Forum. All Rights Reserved.